National Jewish Health
- Type
- Teaching hospital
- Where
- Denver, CO
- Medicare CCN
- 060107
- Received
- $5,056,591 in 339 records, 2020 ($1,937,594 general, $3,118,996 research)
- Source
- CMS Open Payments search ↗
On this site
- Business registration: National Jewish Health Fuzzy (name and state)
- Business registration: National Jewish Health Fuzzy (name and state)
- Business registration: NATIONAL JEWISH HEALTH Fuzzy (name and state)
- Business registration: NATIONAL JEWISH HEALTH Fuzzy (name and state)
- Business registration: National Jewish Health Company Fuzzy (name and state)
- Business registration: NATIONAL JEWISH HEALTH, INC. Fuzzy (name and state)
- Nonprofit contractor: NATIONAL JEWISH HEALTH Fuzzy (name and state)
- Plan sponsor: NATIONAL JEWISH HEALTH Fuzzy (name and state)
- Federal award recipient: NATIONAL JEWISH HEALTH Fuzzy (name and state)
- Nonprofit: NATIONAL JEWISH HEALTH Fuzzy (name and state)
- Patent assignee: National Jewish Health Fuzzy (name and state)
- Trademark owner: National Jewish Health Fuzzy (name and state)
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2020 | General payment | 100 | $1,937,594 |
| 2020 | Research payment | 239 | $3,118,996 |
By company
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 239 | $3,118,996 |
| Grant | 12 | $1,749,113 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 56 | $111,714 |
| Royalty or License | 18 | $41,079 |
| Space rental or facility fees (teaching hospital only) | 11 | $28,500 |
| Education | 2 | $7,000 |
| Charitable Contribution | 1 | $187 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2020-12-31 | AstraZeneca Pharmaceuticals LP | $11,361 | Research payment | In-kind items and services | A Randomized, Double-blind, Parallel Group, Placebo Controlled Study to Evaluate the Effect of Tezepelumab on Airway Inf | 2020 | |
| 2020-12-31 | Siemens Medical Solutions USA, Inc. | $8,297 | Research payment | Cash or cash equivalent | NJHHumphriesCOPDCombinationCT | 2020 | |
| 2020-12-31 | AstraZeneca Pharmaceuticals LP | $480 | Research payment | In-kind items and services | A Multicentre Randomized Double Blind Placebo Controlled Parallel Group Phase 3 Study to Evaluate the Efficacy and Safet | 2020 | |
| 2020-12-31 | AstraZeneca Pharmaceuticals LP | $265 | Research payment | In-kind items and services | Study to evaluate the efficacy and safety of Tezepelumab in reducing oral corticosteroid use in adults with oral cortico | 2020 | |
| 2020-12-31 | Siemens Medical Solutions USA, Inc. | $187 | Charitable Contribution | In-kind items and services | 2020 | ||
| 2020-12-31 | Aimmune Therapeutics, Inc. | $18 | Research payment | Cash or cash equivalent | PALFORZIA Biological, ALLERGY | A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS | 2020 |
| 2020-12-29 | United Therapeutics Corporation | $3,538 | Research payment | Cash or cash equivalent | TYVASO Drug, PAH | AN OPEN-LABEL EXTENSION STUDY OF INHALED TREPROSTINIL IN SUBJECTS WITH PULMONARY HYPERTENSION DUE TO PARENCHYMAL LUNG DI | 2020 |
| 2020-12-24 | Janssen Research & Development, LLC | $2,612 | Research payment | Cash or cash equivalent | A Phase 3, Prospective, Multicenter, Double-blind, Double-dummy, Randomized, Active-controlled, Parallel-group, Group-se | 2020 | |
| 2020-12-22 | United Therapeutics Corporation | $10,388 | Research payment | Cash or cash equivalent | ORENITRAM Drug, PAH | A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients | 2020 |
| 2020-12-21 | Aimmune Therapeutics, Inc. | $3,998 | Research payment | Cash or cash equivalent | PALFORZIA Biological, ALLERGY | A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS | 2020 |
| 2020-12-20 | Boehringer Ingelheim Pharmaceuticals, Inc. | $124,991 | Research payment | Cash or cash equivalent | A randomized parallel group study evaluating the e | 2020 | |
| 2020-12-18 | Regeneron Pharmaceuticals, Inc. | $716,825 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | EFFECT OF DUPILUMAB (ANTI-IL4RA) ON THE HOST-MICROBE INTERFACE IN ATOPIC DERMATITIS | 2020 |
| 2020-12-18 | Regeneron Pharmaceuticals, Inc. | $5,937 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | EFFECT OF DUPILUMAB (ANTI-IL4RA) ON THE HOST-MICROBE INTERFACE IN ATOPIC DERMATITIS | 2020 |
| 2020-12-18 | Genentech, Inc. | $1,114 | Research payment | Cash or cash equivalent | TECENTRIQ Biological, BioOncology | NEOADJUVANT NSCLC | 2020 |
| 2020-12-17 | Regeneron Pharmaceuticals, Inc. | $940 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEA | 2020 |
| 2020-12-14 | Janssen Research & Development, LLC | $17,616 | Research payment | Cash or cash equivalent | A Phase 3, Prospective, Multicenter, Double-blind, Double-dummy, Randomized, Active-controlled, Parallel-group, Group-se | 2020 | |
| 2020-12-14 | Becton, Dickinson and Company | $5,000 | Education | In-kind items and services | 2020 | ||
| 2020-12-14 | Becton, Dickinson and Company | $5,000 | Royalty or License | Cash or cash equivalent | BD Pharmingen Device, Cell Analysis | 2020 | |
| 2020-12-10 | Regeneron Pharmaceuticals, Inc. | $1,769 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEA | 2020 |
| 2020-12-07 | Genentech, Inc. | $65,581 | Research payment | Cash or cash equivalent | Esbriet Biological, Immunology | STUDY OF EFFICACY AND SAFETY OF PIRFENIDONE IN PATIENTS WITH FIBROTIC HYPERSENSITIVITY PNEUMONITIS | 2020 |
| 2020-12-07 | Genentech, Inc. | $54,008 | Research payment | Cash or cash equivalent | Esbriet Biological, Immunology | STUDY OF EFFICACY AND SAFETY OF PIRFENIDONE IN PATIENTS WITH FIBROTIC HYPERSENSITIVITY PNEUMONITIS | 2020 |
| 2020-12-07 | Genentech, Inc. | $30,048 | Research payment | Cash or cash equivalent | Esbriet Biological, Immunology | STUDY OF EFFICACY AND SAFETY OF PIRFENIDONE IN PATIENTS WITH FIBROTIC HYPERSENSITIVITY PNEUMONITIS | 2020 |
| 2020-12-07 | Genentech, Inc. | $15,024 | Research payment | Cash or cash equivalent | Esbriet Biological, Immunology | STUDY OF EFFICACY AND SAFETY OF PIRFENIDONE IN PATIENTS WITH FIBROTIC HYPERSENSITIVITY PNEUMONITIS | 2020 |
| 2020-12-07 | Amgen Inc. | $1,250 | Royalty or License | Cash or cash equivalent | 2020 | ||
| 2020-12-07 | Amgen Inc. | $1,250 | Royalty or License | Cash or cash equivalent | 2020 | ||
| 2020-12-04 | BioMarin Pharmaceutical Inc. | $3,220 | Research payment | Cash or cash equivalent | Palynziq Drug, PKU | An Open-label Extension Study to Evaluate the Safety and Efficacy of Subcutaneous Injections of Pegvaliase 40 mgday Dos | 2020 |
| 2020-12-02 | Merck Sharp & Dohme LLC | $4,833 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Phase 3, Randomized, Placebo-Controlled Clinical Study to Evaluate the Safety and Efficacy of Stereotactic Body Radiot | 2020 |
| 2020-12-01 | AstraZeneca Pharmaceuticals LP | $29,400 | Grant | Cash or cash equivalent | 2020 | ||
| 2020-12-01 | Incyte Corporation | $2,716 | Research payment | Cash or cash equivalent | TRuE AD1-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis | 2020 | |
| 2020-12-01 | Boehringer Ingelheim Pharma GmbH & Co.KG | $63 | Research payment | In-kind items and services | Emphysema Progression Biomarker Study | 2020 | |
| 2020-12-01 | Boehringer Ingelheim International GmbH | $63 | Research payment | In-kind items and services | OFEV Drug, RESPIRATORY | Nintedanib in PF-ILD (extension) | 2020 |
| 2020-11-30 | Janssen Research & Development, LLC | $6,500 | Research payment | Cash or cash equivalent | Uptravi (Selexipag): the users drug registry | 2020 | |
| 2020-11-27 | Merck Sharp & Dohme LLC | $1,878 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Phase 3, Randomized, Placebo-Controlled Clinical Study to Evaluate the Safety and Efficacy of Stereotactic Body Radiot | 2020 |
| 2020-11-26 | Teva Pharmaceuticals USA, Inc. | $47,280 | Research payment | Cash or cash equivalent | CINQAIR Biological, Respiratory | Reslizumab in the Treatment of EGPA | 2020 |
| 2020-11-25 | LEO Pharma AS | $90,312 | Research payment | Cash or cash equivalent | TRALOKINUMAB: CONFIRMATORY TRIAL IN ADOLESCENTS | 2020 | |
| 2020-11-25 | LEO Pharma AS | $57,500 | Research payment | Cash or cash equivalent | TRALOKINUMAB: CONFIRMATORY TRIAL IN ADOLESCENTS | 2020 | |
| 2020-11-24 | United Therapeutics Corporation | $5,768 | Research payment | Cash or cash equivalent | ORENITRAM Drug, PAH | A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients | 2020 |
| 2020-11-19 | Regeneron Pharmaceuticals, Inc. | $616 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEA | 2020 |
| 2020-11-19 | Regeneron Pharmaceuticals, Inc. | $224 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEA | 2020 |
| 2020-11-19 | Becton, Dickinson and Company | $197 | Royalty or License | Cash or cash equivalent | BD Pharmingen Device, Cell Analysis | 2020 | |
| 2020-11-19 | Becton, Dickinson and Company | $39 | Royalty or License | Cash or cash equivalent | BD Pharmingen Device, Cell Analysis | 2020 | |
| 2020-11-18 | Gilead Sciences, Inc. | $55,293 | Research payment | Cash or cash equivalent | Cayston Drug, RESP | Ultrasensitive detection of reductions in CF airway inflammation | 2020 |
| 2020-11-18 | LEO Pharma AS | $25,937 | Research payment | Cash or cash equivalent | TRALOKINUMAB: CONFIRMATORY TRIAL IN ADOLESCENTS | 2020 | |
| 2020-11-18 | Incyte Corporation | $8,000 | Research payment | Cash or cash equivalent | TRuE AD1-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis | 2020 | |
| 2020-11-18 | Incyte Corporation | $500 | Research payment | Cash or cash equivalent | TRuE AD1-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis | 2020 | |
| 2020-11-18 | Bio-Rad Laboratories, Inc. | $46 | Royalty or License | Cash or cash equivalent | Antibody Device, Market Research | 2020 | |
| 2020-11-10 | Aimmune Therapeutics, Inc. | $2,048 | Research payment | Cash or cash equivalent | PALFORZIA Biological, ALLERGY | REAL-WORLD AR101 MARKET-SUPPORTING EXPERIENCE STUDY IN PEANUT-ALLERGIC CHILDREN, ACTIVE TREATMENT ARM OPEN-LABEL EXTENSI | 2020 |
| 2020-11-06 | Regeneron Pharmaceuticals, Inc. | $11,587 | Research payment | Cash or cash equivalent | KEVZARA Biological, INFLAMMATION AND IMMUNOLOGY | An Adaptive Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study Assessing Efficacy and Safety of Sarilumab for | 2020 |
| 2020-11-06 | Incyte Corporation | $1,363 | Research payment | Cash or cash equivalent | TRuE AD1-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis | 2020 | |
| 2020-11-06 | Incyte Corporation | $1,363 | Research payment | Cash or cash equivalent | PD effects and predictive biomarkers of JAK/STAT inhibition with ruxolitinib in operable head and neck squamous cell car | 2020 | |
| 2020-11-05 | Regeneron Pharmaceuticals, Inc. | $224 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEA | 2020 |
| 2020-11-04 | Incyte Corporation | $9,227 | Research payment | Cash or cash equivalent | TRuE AD1-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis | 2020 | |
| 2020-11-03 | Genentech, Inc. | $124,206 | Research payment | Cash or cash equivalent | Xolair Biological, Immunology | THE IMPACT OF INCREASED IGE | 2020 |
| 2020-11-01 | Boehringer Ingelheim Pharma GmbH & Co.KG | $62 | Research payment | In-kind items and services | Emphysema Progression Biomarker Study | 2020 | |
| 2020-11-01 | Boehringer Ingelheim International GmbH | $62 | Research payment | In-kind items and services | OFEV Drug, RESPIRATORY | Nintedanib in PF-ILD (extension) | 2020 |
| 2020-10-27 | Novartis Pharmaceuticals Corporation | $70,504 | Research payment | Cash or cash equivalent | MAS825F Drug | A PHASE 2, RANDOMIZED, PLACEBO-CONTROLLED, PARTICIPANT AND INVESTIGATOR BLINDED, MULTI-CENTER STUDY TO ASSESS EFFICACY A | 2020 |
| 2020-10-27 | Beckman Coulter, Inc. | $10,000 | Royalty or License | Cash or cash equivalent | 2020 | ||
| 2020-10-27 | Boehringer Ingelheim Limited | $34 | Research payment | In-kind items and services | OFEV Drug, RESPIRATORY | Nintedanib in PF-ILD (extension) | 2020 |
| 2020-10-26 | BioMarin Pharmaceutical Inc. | $7,935 | Research payment | Cash or cash equivalent | Palynziq Drug, PKU | An Open-label Extension Study to Evaluate the Safety and Efficacy of Subcutaneous Injections of Pegvaliase 40 mgday Dos | 2020 |
| 2020-10-22 | Regeneron Pharmaceuticals, Inc. | $560 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEA | 2020 |
| 2020-10-20 | United Therapeutics Corporation | $5,049 | Research payment | Cash or cash equivalent | ORENITRAM Drug, PAH | A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients | 2020 |
| 2020-10-16 | Genentech, Inc. | $1,781 | Research payment | Cash or cash equivalent | TECENTRIQ Biological, BioOncology | NEOADJUVANT NSCLC | 2020 |
| 2020-10-15 | Regeneron Pharmaceuticals, Inc. | $9,786 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, STUDY IN PEDIATRIC SUBJECTS WITH PEANUT ALLERGY TO | 2020 |
| 2020-10-15 | Alexion Pharmaceuticals, Inc. | $7,780 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2020 | ||
| 2020-10-15 | Regeneron Pharmaceuticals, Inc. | $359 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEA | 2020 |
| 2020-10-15 | Regeneron Pharmaceuticals, Inc. | $359 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEA | 2020 |
| 2020-10-15 | Regeneron Pharmaceuticals, Inc. | $359 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEA | 2020 |
| 2020-10-15 | Regeneron Pharmaceuticals, Inc. | $293 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEA | 2020 |
| 2020-10-15 | Regeneron Pharmaceuticals, Inc. | $259 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEA | 2020 |
| 2020-10-15 | Regeneron Pharmaceuticals, Inc. | $259 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEA | 2020 |
| 2020-10-15 | Regeneron Pharmaceuticals, Inc. | $259 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEA | 2020 |
| 2020-10-15 | Regeneron Pharmaceuticals, Inc. | $259 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEA | 2020 |
| 2020-10-14 | United Therapeutics Corporation | $3,626 | Research payment | Cash or cash equivalent | TYVASO Drug, PAH | A MULTICENTER RANDOMIZED DOUBLE-BLINDED PLACEBO-CONTROLLED TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF INHALED TREPROST | 2020 |
| 2020-10-08 | Regeneron Pharmaceuticals, Inc. | $5,058 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, STUDY IN PEDIATRIC SUBJECTS WITH PEANUT ALLERGY TO | 2020 |
| 2020-10-08 | Regeneron Pharmaceuticals, Inc. | $1,275 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEA | 2020 |
| 2020-10-06 | Eli Lilly and Company | $62,154 | Research payment | Cash or cash equivalent | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, CLINICAL TRIAL OF LY3127804 IN PATIENTS WHO ARE HOSPITALIZED WITH PNEUMO | 2020 | |
| 2020-10-01 | Boehringer Ingelheim Pharma GmbH & Co.KG | $62 | Research payment | In-kind items and services | Emphysema Progression Biomarker Study | 2020 | |
| 2020-10-01 | Boehringer Ingelheim International GmbH | $62 | Research payment | In-kind items and services | OFEV Drug, RESPIRATORY | Nintedanib in PF-ILD (extension) | 2020 |
| 2020-09-29 | Boehringer Ingelheim Pharmaceuticals, Inc. | $72 | Research payment | In-kind items and services | Emphysema Progression Biomarker Study | 2020 | |
| 2020-09-28 | GENZYME CORPORATION | $11,133 | Research payment | Cash or cash equivalent | DUPIXENT Biological, Immunology | Open Label Exploratory Study to Evaluate the Effect of Dupilumab on Skin Barrier Function in Patients With Moderate to S | 2020 |
| 2020-09-24 | Regeneron Pharmaceuticals, Inc. | $25,800 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, STUDY IN PEDIATRIC SUBJECTS WITH PEANUT ALLERGY TO | 2020 |
| 2020-09-24 | Regeneron Pharmaceuticals, Inc. | $438 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, STUDY IN PEDIATRIC SUBJECTS WITH PEANUT ALLERGY TO | 2020 |
| 2020-09-24 | Merck Sharp & Dohme LLC | $44 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 3, Randomized, Placebo-Controlled Clinical Study to Evaluate the Safety and Efficacy of Stereotactic Body Radiot | 2020 |
| 2020-09-23 | Regeneron Pharmaceuticals, Inc. | $940 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEA | 2020 |
| 2020-09-17 | Regeneron Pharmaceuticals, Inc. | $2,172 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEA | 2020 |
| 2020-09-17 | Regeneron Pharmaceuticals, Inc. | $1,377 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEA | 2020 |
| 2020-09-16 | E.R. Squibb & Sons, L.L.C. | $95,553 | Research payment | Cash or cash equivalent | Identification of Disease Progression Biomarkers in the National Jewish Health IPF cohort | 2020 | |
| 2020-09-16 | Incyte Corporation | $822 | Research payment | Cash or cash equivalent | PD effects and predictive biomarkers of JAK/STAT inhibition with ruxolitinib in operable head and neck squamous cell car | 2020 | |
| 2020-09-16 | Incyte Corporation | $822 | Research payment | Cash or cash equivalent | TRuE AD1-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis | 2020 | |
| 2020-09-15 | AstraZeneca Pharmaceuticals LP | $1,400 | Research payment | Cash or cash equivalent | A Multicentre Randomized Double Blind Placebo Controlled Parallel Group Phase 3 Study to Evaluate the Efficacy and Safet | 2020 | |
| 2020-09-14 | Boehringer Ingelheim Pharmaceuticals, Inc. | $58,495 | Research payment | Cash or cash equivalent | Interstitial Lung Disease in Early Rheumatoid Arth | 2020 | |
| 2020-09-11 | Genentech, Inc. | $5,000 | Royalty or License | Cash or cash equivalent | Non-Covered Product Drug, None | 2020 | |
| 2020-09-09 | United Therapeutics Corporation | $700 | Research payment | Cash or cash equivalent | TYVASO Drug, PAH | AN OPEN-LABEL EXTENSION STUDY OF INHALED TREPROSTINIL IN SUBJECTS WITH PULMONARY HYPERTENSION DUE TO PARENCHYMAL LUNG DI | 2020 |
| 2020-09-08 | Aimmune Therapeutics, Inc. | $6,117 | Research payment | Cash or cash equivalent | PALFORZIA Biological, ALLERGY | A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS | 2020 |
| 2020-09-08 | Aimmune Therapeutics, Inc. | $2,739 | Research payment | Cash or cash equivalent | PALFORZIA Biological, ALLERGY | A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS | 2020 |
| 2020-09-08 | Incyte Corporation | $117 | Research payment | Cash or cash equivalent | An Open Label, Pilot Pharmacokinetic Study of INCB018424 Phosphate Cream in Pediatric Subjects With Atopic Dermatitis | 2020 | |
| 2020-09-04 | SANOFI US SERVICES INC. | $1,542 | Research payment | Cash or cash equivalent | DUPIXENT Biological, Immunology | Open-label, Interventional, Cohort Study to Evaluate Long-term Safety of Dupilumab in Patients With Moderate to Severe A | 2020 |
| 2020-09-03 | BioMarin Pharmaceutical Inc. | $14,775 | Research payment | Cash or cash equivalent | Palynziq Drug, PKU | An Open-label Extension Study to Evaluate the Safety and Efficacy of Subcutaneous Injections of Pegvaliase 40 mgday Dos | 2020 |
| 2020-09-01 | Eli Lilly and Company | $10,000 | Research payment | Cash or cash equivalent | 2020 | ||
| 2020-09-01 | Boehringer Ingelheim International GmbH | $60 | Research payment | In-kind items and services | OFEV Drug, RESPIRATORY | Nintedanib in PF-ILD (extension) | 2020 |
| 2020-09-01 | Boehringer Ingelheim Pharma GmbH & Co.KG | $60 | Research payment | In-kind items and services | Emphysema Progression Biomarker Study | 2020 | |
| 2020-08-26 | Merck Sharp & Dohme LLC | $452 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 3, Randomized, Placebo-Controlled Clinical Study to Evaluate the Safety and Efficacy of Stereotactic Body Radiot | 2020 |
| 2020-08-26 | Boehringer Ingelheim Pharma GmbH & Co.KG | $90 | Research payment | In-kind items and services | Emphysema Progression Biomarker Study | 2020 | |
| 2020-08-25 | Becton, Dickinson and Company | $120 | Royalty or License | Cash or cash equivalent | BD Pharmingen Device, Cell Analysis | 2020 | |
| 2020-08-20 | Regeneron Pharmaceuticals, Inc. | $3,971 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEA | 2020 |
| 2020-08-18 | EMD Millipore Corporation | $30 | Royalty or License | Cash or cash equivalent | Device, DIAGNOSTIC TESTING | 2020 | |
| 2020-08-14 | Regeneron Pharmaceuticals, Inc. | $8,976 | Research payment | Cash or cash equivalent | KEVZARA Biological, INFLAMMATION AND IMMUNOLOGY | An Adaptive Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study Assessing Efficacy and Safety of Sarilumab for | 2020 |
| 2020-08-14 | Regeneron Pharmaceuticals, Inc. | $6,627 | Research payment | Cash or cash equivalent | KEVZARA Biological, INFLAMMATION AND IMMUNOLOGY | An Adaptive Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study Assessing Efficacy and Safety of Sarilumab for | 2020 |
| 2020-08-14 | Regeneron Pharmaceuticals, Inc. | $6,396 | Research payment | Cash or cash equivalent | KEVZARA Biological, INFLAMMATION AND IMMUNOLOGY | An Adaptive Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study Assessing Efficacy and Safety of Sarilumab for | 2020 |
| 2020-08-14 | Regeneron Pharmaceuticals, Inc. | $4,647 | Research payment | Cash or cash equivalent | KEVZARA Biological, INFLAMMATION AND IMMUNOLOGY | An Adaptive Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study Assessing Efficacy and Safety of Sarilumab for | 2020 |
| 2020-08-14 | Regeneron Pharmaceuticals, Inc. | $2,578 | Research payment | Cash or cash equivalent | KEVZARA Biological, INFLAMMATION AND IMMUNOLOGY | An Adaptive Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study Assessing Efficacy and Safety of Sarilumab for | 2020 |
| 2020-08-14 | Bio-Rad Laboratories, Inc. | $1,899 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Liquichek Device, Controls | 2020 | |
| 2020-08-12 | CSL Behring | $750 | Research payment | Cash or cash equivalent | Study NJH-A1520 - Referral Lab Testing | 2020 | |
| 2020-08-09 | Boehringer Ingelheim Pharmaceuticals, Inc. | $5 | Research payment | In-kind items and services | OFEV Drug, RESPIRATORY | Nintedanib in PF ILD extension | 2020 |
| 2020-08-06 | ABBVIE INC. | $970 | Research payment | Cash or cash equivalent | CREON Drug, ENDOCRINOLOGY | P12-792 | 2020 |
| 2020-08-06 | VIVUS LLC | $326 | Research payment | Cash or cash equivalent | PANCREAZE Drug, CYSTIC FIBROSIS | Long-term Study in US Cystic Fibrosis | 2020 |
| 2020-08-03 | Incyte Corporation | $28,453 | Research payment | Cash or cash equivalent | An Open Label, Pilot Pharmacokinetic Study of INCB018424 Phosphate Cream in Pediatric Subjects With Atopic Dermatitis | 2020 | |
| 2020-08-01 | VERTEX PHARMACEUTICALS INCORPORATED | $14,641 | Research payment | Cash or cash equivalent | Evaluation of the Efficacy and Safety of VX-864 in Subjects With the PiZZ Genotype | 2020 | |
| 2020-08-01 | Alexion Pharmaceuticals, Inc. | $7,200 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2020 | ||
| 2020-08-01 | Boehringer Ingelheim International GmbH | $60 | Research payment | In-kind items and services | OFEV Drug, RESPIRATORY | Nintedanib in PF-ILD (extension) | 2020 |
| 2020-08-01 | Boehringer Ingelheim Pharma GmbH & Co.KG | $60 | Research payment | In-kind items and services | Emphysema Progression Biomarker Study | 2020 | |
| 2020-07-30 | Regeneron Pharmaceuticals, Inc. | $7,770 | Research payment | Cash or cash equivalent | Sample acquisition study from Eculizumab treated CHAPLE patients and health patients for understanding disease biomarker | 2020 | |
| 2020-07-29 | Incyte Corporation | $6,609 | Research payment | Cash or cash equivalent | TRuE AD1-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis | 2020 | |
| 2020-07-28 | Regeneron Pharmaceuticals, Inc. | $4,444 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEA | 2020 |
| 2020-07-24 | Regeneron Pharmaceuticals, Inc. | $6,305 | Research payment | Cash or cash equivalent | KEVZARA Biological, INFLAMMATION AND IMMUNOLOGY | An Adaptive Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study Assessing Efficacy and Safety of Sarilumab for | 2020 |
| 2020-07-23 | Regeneron Pharmaceuticals, Inc. | $7,337 | Research payment | Cash or cash equivalent | KEVZARA Biological, INFLAMMATION AND IMMUNOLOGY | An Adaptive Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study Assessing Efficacy and Safety of Sarilumab for | 2020 |
| 2020-07-22 | AstraZeneca Pharmaceuticals LP | $50,176 | Research payment | Cash or cash equivalent | FASENRA Drug, Respiratory | Benralizumab in the Treatment of EGPA Study | 2020 |
| 2020-07-16 | Regeneron Pharmaceuticals, Inc. | $2,183 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEA | 2020 |
| 2020-07-13 | Actelion Pharmaceuticals, Ltd | $26,454 | Research payment | Cash or cash equivalent | OPsumit Users Registry | 2020 | |
| 2020-07-10 | Regeneron Pharmaceuticals, Inc. | $10,333 | Research payment | Cash or cash equivalent | KEVZARA Biological, INFLAMMATION AND IMMUNOLOGY | An Adaptive Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study Assessing Efficacy and Safety of Sarilumab for | 2020 |
| 2020-07-09 | Boehringer Ingelheim Pharma GmbH & Co.KG | $34,606 | Research payment | Cash or cash equivalent | Research Collaboration | 2020 | |
| 2020-07-09 | Regeneron Pharmaceuticals, Inc. | $5,195 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, STUDY IN PEDIATRIC SUBJECTS WITH PEANUT ALLERGY TO | 2020 |
| 2020-07-02 | Regeneron Pharmaceuticals, Inc. | $9,748 | Research payment | Cash or cash equivalent | KEVZARA Biological, INFLAMMATION AND IMMUNOLOGY | An Adaptive Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study Assessing Efficacy and Safety of Sarilumab for | 2020 |
| 2020-07-02 | Regeneron Pharmaceuticals, Inc. | $9,437 | Research payment | Cash or cash equivalent | KEVZARA Biological, INFLAMMATION AND IMMUNOLOGY | An Adaptive Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study Assessing Efficacy and Safety of Sarilumab for | 2020 |
| 2020-07-01 | Genentech, Inc. | $10,094 | Research payment | Cash or cash equivalent | TECENTRIQ Biological, BioOncology | NEOADJUVANT NSCLC | 2020 |
| 2020-07-01 | Aimmune Therapeutics, Inc. | $5,823 | Research payment | Cash or cash equivalent | PALFORZIA Biological, ALLERGY | A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS | 2020 |
| 2020-07-01 | Boehringer Ingelheim Pharma GmbH & Co.KG | $60 | Research payment | In-kind items and services | Emphysema Progression Biomarker Study | 2020 | |
| 2020-07-01 | Boehringer Ingelheim International GmbH | $60 | Research payment | In-kind items and services | OFEV Drug, RESPIRATORY | Nintedanib in PF-ILD (extension) | 2020 |
| 2020-06-26 | Regeneron Pharmaceuticals, Inc. | $8,231 | Research payment | Cash or cash equivalent | KEVZARA Biological, INFLAMMATION AND IMMUNOLOGY | An Adaptive Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study Assessing Efficacy and Safety of Sarilumab for | 2020 |
| 2020-06-18 | Regeneron Pharmaceuticals, Inc. | $6,806 | Research payment | Cash or cash equivalent | KEVZARA Biological, INFLAMMATION AND IMMUNOLOGY | An Adaptive Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study Assessing Efficacy and Safety of Sarilumab for | 2020 |
| 2020-06-18 | Regeneron Pharmaceuticals, Inc. | $1,557 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEA | 2020 |
| 2020-06-11 | LEO Pharma AS | $34,062 | Research payment | Cash or cash equivalent | TRALOKINUMAB: CONFIRMATORY TRIAL IN ADOLESCENTS | 2020 | |
| 2020-06-11 | Regeneron Pharmaceuticals, Inc. | $9,127 | Research payment | Cash or cash equivalent | KEVZARA Biological, INFLAMMATION AND IMMUNOLOGY | An Adaptive Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study Assessing Efficacy and Safety of Sarilumab for | 2020 |
| 2020-06-11 | Regeneron Pharmaceuticals, Inc. | $7,628 | Research payment | Cash or cash equivalent | KEVZARA Biological, INFLAMMATION AND IMMUNOLOGY | An Adaptive Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study Assessing Efficacy and Safety of Sarilumab for | 2020 |
| 2020-06-11 | Regeneron Pharmaceuticals, Inc. | $7,628 | Research payment | Cash or cash equivalent | KEVZARA Biological, INFLAMMATION AND IMMUNOLOGY | An Adaptive Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study Assessing Efficacy and Safety of Sarilumab for | 2020 |
| 2020-06-11 | Regeneron Pharmaceuticals, Inc. | $7,409 | Research payment | Cash or cash equivalent | KEVZARA Biological, INFLAMMATION AND IMMUNOLOGY | An Adaptive Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study Assessing Efficacy and Safety of Sarilumab for | 2020 |
| 2020-06-11 | Regeneron Pharmaceuticals, Inc. | $7,026 | Research payment | Cash or cash equivalent | KEVZARA Biological, INFLAMMATION AND IMMUNOLOGY | An Adaptive Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study Assessing Efficacy and Safety of Sarilumab for | 2020 |
| 2020-06-11 | Regeneron Pharmaceuticals, Inc. | $6,806 | Research payment | Cash or cash equivalent | KEVZARA Biological, INFLAMMATION AND IMMUNOLOGY | An Adaptive Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study Assessing Efficacy and Safety of Sarilumab for | 2020 |
| 2020-06-11 | Regeneron Pharmaceuticals, Inc. | $6,514 | Research payment | Cash or cash equivalent | KEVZARA Biological, INFLAMMATION AND IMMUNOLOGY | An Adaptive Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study Assessing Efficacy and Safety of Sarilumab for | 2020 |
| 2020-06-11 | Regeneron Pharmaceuticals, Inc. | $3,513 | Research payment | Cash or cash equivalent | KEVZARA Biological, INFLAMMATION AND IMMUNOLOGY | An Adaptive Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study Assessing Efficacy and Safety of Sarilumab for | 2020 |
| 2020-06-04 | Regeneron Pharmaceuticals, Inc. | $2,929 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEA | 2020 |
| 2020-06-04 | Regeneron Pharmaceuticals, Inc. | $690 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, STUDY IN PEDIATRIC SUBJECTS WITH PEANUT ALLERGY TO | 2020 |
| 2020-06-04 | Regeneron Pharmaceuticals, Inc. | $562 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, STUDY IN PEDIATRIC SUBJECTS WITH PEANUT ALLERGY TO | 2020 |
| 2020-06-04 | Regeneron Pharmaceuticals, Inc. | $300 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, STUDY IN PEDIATRIC SUBJECTS WITH PEANUT ALLERGY TO | 2020 |
| 2020-06-04 | Regeneron Pharmaceuticals, Inc. | $248 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, STUDY IN PEDIATRIC SUBJECTS WITH PEANUT ALLERGY TO | 2020 |
| 2020-06-03 | Takeda Pharmaceuticals U.S.A., Inc. | $12,593 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | TAKHZYRO Biological, IMMUNOLOGY | 2020 | |
| 2020-06-03 | Takeda Pharmaceuticals U.S.A., Inc. | $7,214 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | TAKHZYRO Biological, IMMUNOLOGY | 2020 | |
| 2020-06-03 | Takeda Pharmaceuticals U.S.A., Inc. | $6,628 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | TAKHZYRO Biological, IMMUNOLOGY | 2020 | |
| 2020-06-03 | Takeda Pharmaceuticals U.S.A., Inc. | $5,372 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | TAKHZYRO Biological, IMMUNOLOGY | 2020 | |
| 2020-06-03 | Takeda Pharmaceuticals U.S.A., Inc. | $2,758 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | TAKHZYRO Biological, IMMUNOLOGY | 2020 | |
| 2020-06-01 | Ipsen Bioscience Inc. | $4,099 | Research payment | Cash or cash equivalent | ONIVYDE Drug, Oncology | RESILIENT A Randomized, Open Label Phase 3 Study of Irinotecan Liposome Injection ONIVYDE Versus Topotecan in Patients W | 2020 |
| 2020-06-01 | Alexion Pharmaceuticals, Inc. | $212 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2020 | ||
| 2020-06-01 | Alexion Pharmaceuticals, Inc. | $212 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2020 | ||
| 2020-06-01 | Alexion Pharmaceuticals, Inc. | $212 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2020 | ||
| 2020-06-01 | Alexion Pharmaceuticals, Inc. | $212 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2020 | ||
| 2020-06-01 | Alexion Pharmaceuticals, Inc. | $212 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2020 | ||
| 2020-06-01 | Alexion Pharmaceuticals, Inc. | $212 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2020 | ||
| 2020-06-01 | Alexion Pharmaceuticals, Inc. | $212 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2020 | ||
| 2020-06-01 | Alexion Pharmaceuticals, Inc. | $212 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2020 | ||
| 2020-06-01 | Alexion Pharmaceuticals, Inc. | $212 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2020 | ||
| 2020-06-01 | Alexion Pharmaceuticals, Inc. | $212 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2020 | ||
| 2020-06-01 | Alexion Pharmaceuticals, Inc. | $212 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2020 | ||
| 2020-06-01 | Alexion Pharmaceuticals, Inc. | $212 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2020 | ||
| 2020-06-01 | Alexion Pharmaceuticals, Inc. | $212 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2020 | ||
| 2020-06-01 | Alexion Pharmaceuticals, Inc. | $212 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2020 | ||
| 2020-06-01 | Alexion Pharmaceuticals, Inc. | $212 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2020 | ||
| 2020-06-01 | Alexion Pharmaceuticals, Inc. | $212 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2020 | ||
| 2020-06-01 | Alexion Pharmaceuticals, Inc. | $212 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2020 | ||
| 2020-06-01 | Alexion Pharmaceuticals, Inc. | $212 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2020 | ||
| 2020-06-01 | Alexion Pharmaceuticals, Inc. | $212 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2020 | ||
| 2020-06-01 | Alexion Pharmaceuticals, Inc. | $212 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2020 | ||
| 2020-06-01 | Alexion Pharmaceuticals, Inc. | $212 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2020 | ||
| 2020-06-01 | Alexion Pharmaceuticals, Inc. | $212 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2020 | ||
| 2020-06-01 | Alexion Pharmaceuticals, Inc. | $212 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2020 | ||
| 2020-06-01 | Alexion Pharmaceuticals, Inc. | $212 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2020 | ||
| 2020-06-01 | Alexion Pharmaceuticals, Inc. | $212 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2020 | ||
| 2020-06-01 | Alexion Pharmaceuticals, Inc. | $212 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2020 | ||
| 2020-06-01 | Alexion Pharmaceuticals, Inc. | $212 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2020 | ||
| 2020-06-01 | Alexion Pharmaceuticals, Inc. | $212 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2020 | ||
| 2020-06-01 | Alexion Pharmaceuticals, Inc. | $212 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2020 | ||
| 2020-06-01 | Alexion Pharmaceuticals, Inc. | $212 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2020 | ||
| 2020-06-01 | Alexion Pharmaceuticals, Inc. | $212 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2020 | ||
| 2020-06-01 | Alexion Pharmaceuticals, Inc. | $212 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2020 | ||
| 2020-06-01 | Alexion Pharmaceuticals, Inc. | $212 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2020 | ||
| 2020-06-01 | Alexion Pharmaceuticals, Inc. | $212 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2020 | ||
| 2020-06-01 | Alexion Pharmaceuticals, Inc. | $212 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2020 | ||
| 2020-06-01 | Alexion Pharmaceuticals, Inc. | $212 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2020 | ||
| 2020-06-01 | Alexion Pharmaceuticals, Inc. | $212 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2020 | ||
| 2020-06-01 | Alexion Pharmaceuticals, Inc. | $212 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2020 | ||
| 2020-06-01 | Alexion Pharmaceuticals, Inc. | $212 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2020 |
The latest 200 records of 339.
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Denver, CO, county Denver County, CO, state Colorado; placed by its city name.
| Measure | Place (city or town) Denver, CO | County Denver County, CO | State Colorado |
|---|---|---|---|
| Population B01003 | 718,877 | 718,877 | 5,862,189 |
| Population, 2020 census P1 | 715,522 | 715,522 | 5,773,714 |
| Median age B01002 | 35.3 | 35.3 | 37.7 |
| Under 18 B01001 | 18.0% | 18.0% | 21.0% |
| 65 and over B01001 | 12.5% | 12.5% | 15.6% |
| Households B11001 | 335,428 | 335,428 | 2,374,218 |
| Foreign born B05002 | 14.5% | 14.5% | 9.8% |
| Median household income B19013 | $94,718 | $94,718 | $95,470 |
| Median family income B19113 | $124,743 | $124,743 | $119,139 |
| Per capita income B19301 | $64,163 | $64,163 | $52,636 |
| Poverty rate B17001 | 11.2% | 11.2% | 9.4% |
| Unemployment rate B23025 | 4.9% | 4.9% | 4.6% |
| Civilian labor force B23025 | 447,681 | 447,681 | 3,235,476 |
| Mean commute (minutes) B08013 | 24.9 | 24.9 | 25.2 |
| Bachelor's degree or higher B15003 | 56.5% | 56.5% | 45.7% |
| Housing units B25001 | 359,581 | 359,581 | 2,589,053 |
| Owner-occupied B25003 | 48.8% | 48.8% | 66.2% |
| Renters B25003 | 51.2% | 51.2% | 33.8% |
| Median home value B25077 | $616,000 | $616,000 | $539,400 |
| Median gross rent B25064 | $1,831 | $1,831 | $1,761 |
| White, not Hispanic B03002 | 54.0% | 54.0% | 64.8% |
| Black B03002 | 8.6% | 8.6% | 3.8% |
| Hispanic or Latino B03002 | 28.0% | 28.0% | 22.5% |
| Asian B03002 | 3.6% | 3.6% | 3.2% |
| American Indian and Alaska Native B03002 | 0.3% | 0.3% | 0.4% |
Economy now FRED unemployment 4.1% in Sep 2026 (3.8% a year earlier); per capita personal income $86,342 in 2025, up 34% in five years (+7.3% after inflation); the state; Source: FRED, Federal Reserve Bank of St. Louis.
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Denver, CO.
Comments